Oral Wegovy, Mounjaro & The Future of Weight Loss: The Best Prescription Treatments in the UK

The weight loss treatment landscape is evolving faster than ever. Just a few years ago, patients seeking medical support for weight management had limited options. Today, treatments such as Wegovy® and Mounjaro® are helping thousands of people across the UK achieve significant weight loss and improve their overall health.

But perhaps the biggest development isn't what's available now. It's what's coming next.

From the world's first highly effective prescription weight loss pills to next-generation medications that may outperform today's injections, obesity treatment is entering a new era.

So what actually works today, and what treatments could soon change weight management forever?

Let's take a closer look.

Why Weight Loss Treatment Has Changed Forever

For decades, weight management was largely viewed as a matter of willpower. Eat less. Exercise more. Try harder. We now know obesity is far more complex than that.

Body weight is influenced by hormones, genetics, appetite regulation, metabolism, medications, sleep quality, stress levels and numerous other biological factors. Modern weight loss medicines work by targeting the body's natural appetite-control systems. Instead of constantly battling hunger, patients often find themselves naturally eating less because they simply don't feel as hungry. This scientific breakthrough is why treatments such as Wegovy and Mounjaro have generated so much attention worldwide.

The Current Leaders: Wegovy and Mounjaro

At present, two treatments dominate conversations around prescription weight loss in the UK.

Wegovy®

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a naturally occurring hormone involved in appetite regulation.

It helps patients:

• Feel fuller for longer
• Reduce food cravings
• Eat smaller portions
• Maintain a calorie deficit more comfortably

Wegovy is approved for chronic weight management and is also licensed for use in eligible adolescents aged 12 years and above.

Importantly, Wegovy has received approval for reducing the risk of major cardiovascular events in certain adults with established cardiovascular disease and obesity or overweight.

It is also recognised for benefits relating to obesity-associated knee health in eligible patients.

Mounjaro®

Mounjaro contains tirzepatide and works slightly differently.

Rather than targeting one hormone pathway, it activates both GLP-1 and GIP receptors.

This dual-action approach has delivered some of the most impressive weight loss results ever seen from a prescription medicine.

Many patients report:

• Reduced appetite
• Less food noise
• Greater feelings of fullness
• Improved control over eating habits

For adults seeking maximum weight loss results, Mounjaro has become one of the most sought-after prescription treatments available.

The Biggest Innovation: Weight Loss Pills Are Coming

One of the main reasons some people hesitate to start treatment is the idea of weekly injections.

Even though the injection devices are simple to use and feature tiny needles, many patients would prefer a tablet.

For years, this was a major challenge.

GLP-1 medicines are protein-based molecules that are easily broken down by the digestive system, making effective oral treatment difficult.

That challenge may finally have been solved.

Oral Wegovy: The Weight Loss Tablet Generating Global Attention

Novo Nordisk, the manufacturer behind Wegovy, has been developing an oral version of semaglutide.

This has attracted enormous interest because it could become one of the first highly effective weight loss tablets capable of delivering results comparable to injectable treatments. Each tablet has to be taken on an empty stomach with a small amount of water. 

Early trial data has been extremely encouraging, with initial data showing the oral formulation being just as effective as wegovy 2.4mg injections. 

Patients taking oral semaglutide achieved substantial weight loss while benefiting from the convenience of a daily tablet.

For many people, this could remove one of the biggest psychological barriers to starting treatment.

Instead of a weekly injection, patients may eventually be able to take a tablet as part of their daily routine.

While regulatory approvals continue to progress, oral semaglutide is widely viewed as one of the most important developments in obesity treatment in recent years.

Could Weight Loss Pills Replace Injections?

Possibly. But not immediately.

Injectable treatments currently have a strong track record and extensive real-world experience behind them.

Many healthcare professionals believe injections will remain an important treatment option for years to come.

However, tablets could significantly expand access to treatment by appealing to people who are uncomfortable with injections.

The future is likely to involve both options, allowing patients and healthcare professionals to choose the most appropriate treatment based on individual needs and preferences.

Eli Lilly's Orforglipron: Another Major Breakthrough

While Novo Nordisk is developing oral semaglutide, Eli Lilly is developing an entirely different oral medication called Orforglipron.

This treatment has generated considerable excitement within the medical community.

Unlike current GLP-1 medications, Orforglipron is a small molecule drug designed specifically to be taken orally.

Early clinical studies have demonstrated promising weight loss outcomes and suggest it could become a major competitor to both Wegovy and Mounjaro.

If approved, Orforglipron could represent the next phase of obesity treatment by combining the effectiveness of modern GLP-1 therapies with the convenience of a daily tablet.

What Could the Future of Weight Loss Treatment Look Like?

• Researchers are already investigating:
• More effective oral medications
• Triple-hormone therapies
• Personalised obesity treatments
• Combination therapies targeting multiple metabolic pathways
• Treatments designed to preserve muscle mass during weight loss

Many experts believe the next decade could transform obesity management as dramatically as statins transformed cardiovascular care.

The goal is no longer simply helping patients lose weight.

The goal is improving long-term health outcomes, reducing obesity-related diseases and helping people maintain healthier weights for life.

Should You Wait for New Treatments?

This is one of the most common questions patients ask.

The reality is that effective treatments already exist today.

Waiting for future innovations may mean delaying improvements to your health, mobility and quality of life.

Current medications such as Wegovy and Mounjaro have already helped countless patients achieve meaningful weight loss while reducing obesity-related health risks.

Future medications may offer additional convenience, but today's treatments are already delivering life-changing results.

The Bottom Line

The UK weight loss treatment market is evolving rapidly.

Today, Wegovy and Mounjaro remain the leading prescription weight loss treatments available through regulated providers such as 24 HR Pharmacy.

However, the future looks incredibly exciting.

The development of oral Wegovy and next-generation treatments such as Orforglipron could make prescription weight loss treatment more accessible and convenient than ever before.

For patients considering weight management support today, the good news is that highly effective treatments are already available, while even more innovations continue to emerge on the horizon.

As obesity medicine advances, patients will have more choice, more convenience and more opportunities than ever before to achieve sustainable, long-term weight loss.